University of Colorado, Division of Medical Oncology, 12801 E. 17th Avenue, Mail Stop 8117, Research 1 South, Aurora, CO, USA.
Alexandra Hospital, National and Kapodistrian University of Athens School of Medicine, Department of Clinical Therapeutics, Alexandra Hospital, 80 Vasilisis Sofias Avenue, Athens, Greece.
Lung Cancer. 2019 Jul;133:56-61. doi: 10.1016/j.lungcan.2019.05.004. Epub 2019 May 6.
Inhibitors of the hedgehog pathway are effective in patients with basal cell carcinoma and a subgroup of patients with medulloblastoma with active hedgehog signaling. Despite preclinical work suggesting otherwise, clinical trials in solid tumors of epithelial origin have not shown added benefit with these drugs. Here, we review the preclinical and clinical data of hedgehog pathway inhibition in the most common histologic types of lung cancer. We focus on highlighting areas of uncertainty, where further research might define a niche for hedgehog pathway inhibition in patients with lung cancer.
hedgehog 通路抑制剂在基底细胞癌患者和具有活跃 hedgehog 信号的髓母细胞瘤亚组患者中有效。尽管临床前研究表明并非如此，但在源自上皮组织的实体瘤的临床试验中，这些药物并未显示出额外的益处。在这里，我们回顾了 hedgehog 通路抑制在最常见的肺癌组织学类型中的临床前和临床数据。我们重点强调了不确定的领域，在这些领域中，进一步的研究可能会为肺癌患者 hedgehog 通路抑制确定一个合适的治疗方向。
